AKUMS Akums Drugs Q4 FY26 results (Jan–Mar 2026) and concall
Akums Drugs reported a strong Q4 and full year FY26, with healthy revenue and EBITDA margin expansion driven by robust CDMO performance and the turnaround of trade generics. Strategic investments in capacity and R&D continue, alongside securing significant long-term contracts in Europe and Zambia. While the API business remains a drag, management expects reduced losses and a return to growth in international branded formulations.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 2.7%, net profit down 46.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 328 | 337 | 329 | 332 | 309 −6% | 369 +9% | 338 +3% |
| EBITDA | 43 | 34 | 18 | 44 | 17 −60% | 25 −26% | 12 −33% |
| Net profit | 50 | 41 | 28 | 45 | 23 −54% | 28 −32% | 15 −46% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
